Lilly’s Mirikizumab Offers Long-term Remission

Eli Lilly has announced promising, multi-year results from two Phase 3 studies showing that mirikizumab helped patients with ulcerative colitis (UC) and Crohn's disease achieve lasting remission. Data from the LUCENT-3 and VIVID-2 studies, to be presented at the American College of Gastroenterology's Annual Meeting, highlight mirikizumab’s effectiveness in managing these conditions. Results showed patients maintained stable clinical remission and endoscopic healing over several years, suggesting mirikizumab could provide significant relief from symptoms such as bowel urgency.

In patients with moderately to severely active UC, 81% sustained remission with mirikizumab over three years, with positive results in mucosal healing and symptom improvement. For those with Crohn’s disease, the study extended to five years, with 87% achieving long-term remission and 76% showing endoscopic response. These benefits were supported by a favorable safety profile.

Approved in the U.S. for UC, mirikizumab is currently under regulatory review for Crohn’s disease worldwide. Lilly has also begun additional studies combining mirikizumab with other potential therapies to further improve outcomes for people living with IBD.